

## **Xanamem™ research published in prestigious medical journal**

- First results published of Xanamem™ research from human trials.
- Results show Xanamem™ is safe and well tolerated with no major safety issues.
- Confirms the brain penetrating properties of Xanamem™ and that it reaches the brain at concentrations predicted to inhibit excess cortisol production in the brain.
- Concludes that Xanamem™ is a good candidate to further investigate as a treatment for Alzheimer's disease.

**Sydney, Australia – 9th February 2017:** Actinogen Medical is pleased to announce the Xanamem™ research paper: *Selection and early clinical evaluation of the brain-penetrant 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor UE2343 (Xanamem™)* has been published in the prestigious British Journal of Pharmacology (BJP). The full paper is available at: <http://actinogen.com.au>

This paper describes the research underpinning the development of Xanamem at the University of Edinburgh over the last 10 years. It summarises the results achieved from the early research studies that confirmed Xanamem to be the optimum candidate drug to take forward to clinical development in Alzheimer's disease. The paper details the results achieved in the Phase I studies in humans, which confirmed the safety of Xanamem in humans and helped with the selection of the optimal dose for Xanamem, to use in future research. Most significantly, the research data confirmed that Xanamem crosses the blood-brain-barrier in concentrations sufficient to inhibit the production of excess cortisol in the brain.

The paper discusses in some detail, the ability of Xanamem to inhibit the 11β-HSD1 enzyme in the brain, its primary site of action. Inhibition of the enzyme blocks the production of excess cortisol in the brain.

Xanamem™ has been specifically designed to block production of cortisol, the stress hormone, in the areas of the brain most affected in Alzheimer's disease. Raised cortisol has been strongly associated with Alzheimer's disease and lowering cortisol in the brain is an important new target for treating Alzheimer's disease.

As previously announced, Actinogen is about to start enrolling patients into XanADu, a Phase II trial of Xanamem in Alzheimer's disease. The first patients are expected to be treated with Xanamem on this trial in early Q2 2017.

The trial: **XanADu: A Phase II Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to assess the safety, tolerability and efficacy of Xanamem™ in subjects with mild dementia due to Alzheimer's disease**, will enrol 174 patients at research sites across the Australia, the UK and the USA. The trial is registered on [www.clinicaltrials.gov](http://www.clinicaltrials.gov) with the identifier: NCT02727699.

**ENDS**

### **Actinogen Medical**

Dr. Bill Ketelbey

CEO & Managing Director

P: +61 2 8964 7401

E: [bill.ketelbey@actinogen.com.au](mailto:bill.ketelbey@actinogen.com.au)

 @BillKetelbey

## **About Actinogen Medical**

Actinogen Medical (ASX: ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and metabolic diseases. Xanamem™, Actinogen Medical's lead candidate drug, blocks excess production of the stress hormone cortisol in the brain. There is growing evidence that chronic stress and excess cortisol leads to changes in the brain affecting memory, and to the development of amyloid plaques and neural death – all hallmarks of Alzheimer's disease. In 2016, the Company initiated XanADu, a Phase II efficacy and safety trial of Xanamem™ in mild Alzheimer's disease.

## **About Xanamem™**

Xanamem™ is being developed as a promising new therapy for Alzheimer's disease, a condition with a multibillion dollar market potential. In the US alone, the cost of managing Alzheimer's disease in 2013 was estimated to be US\$250bn, and is set to increase to US\$1 trillion by 2050, outstripping the treatment costs of all other diseases. Alzheimer's disease is now the leading cause of death in the UK and second only to ischaemic heart disease in Australia. Xanamem™'s novel mechanism of action sets it apart from other Alzheimer's treatments. It works by blocking the excess production of cortisol - the stress hormone - in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer's disease.

Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.